Big Pharma Sharma

Revolution Medicines presented complete Phase 3 data for daraxonrasib at ASCO 2026, showing the drug cut the risk of death by 60% and nearly doubled median overall survival to 13.2 months versus 6.7 m…

Eli Lilly reported positive interim Phase 1b data for its in vivo PCSK9 base editor VERVE-102, showing single-dose LDL-C reductions of up to 62% sustained for 18 months in patients with heterozygous f…